Abstract:In order to examine its clinical efficacy, recombinant human interferon-beta (rIFN-beta) was instilled intravesically into 51 patients with superficial bladder cancer. Ten patients, who received intermittent intravesical instillation at a dose of (3-36) x 10(6) U rIFN-beta on days 1-3 every week, showed no response. Thirty-two patients received intravesical instillation at a dose of (3-36) x 10(6) U every day for 10-20 days. Eight patients showed partial response, indicating an efficacy rate of 25%. Nine patie… Show more
“…For a variety of different regimens response rates between 0 and 55% have been reported in patients with TIS of the bladder [5157]. Reports on the topical application of other IFNs comprise only casuistic observations, not allowing any conclusions regarding the efficacy of these agents [58].…”
Section: Non-bcg Immunotherapy Of Superficial Bladder Cancermentioning
“…For a variety of different regimens response rates between 0 and 55% have been reported in patients with TIS of the bladder [5157]. Reports on the topical application of other IFNs comprise only casuistic observations, not allowing any conclusions regarding the efficacy of these agents [58].…”
Section: Non-bcg Immunotherapy Of Superficial Bladder Cancermentioning
“…The current clinical experience with intravesical IFN-β or -γ is limited, but preliminary results with the latter are somewhat disappointing [24, 25]. …”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.